Base de dados : MEDLINE
Pesquisa : Raquitismo [Palavras]
Referências encontradas : 7464 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 747 ir para página                         

  1 / 7464 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28506344
[Au] Autor:Ran Q; Xiong F; Zhu M; Deng LL; Lei PY; Luo YH; Zeng Y; Zhu GH; Song C
[Ad] Endereço:Department of Endocrinology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China. xiongfengw@163.com.
[Ti] Título:[Novel PHEX gene mutations in patients with X-linked hypophosphatemic rickets: an analysis of 2 cases].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(5):534-538, 2017 May.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To investigate PHEX gene mutations in 2 patients with X-linked hypophosphatemic rickets (XLH) and their families and to clarify the genetic etiology. METHODS: A retrospective analysis was performed for the clinical data of two patients with XLH. High-throughput sequencing was used to detect the PHEX gene, a pathogenic gene of XLH. PCR-Sanger sequencing was used to verify the distribution of mutations in families. RESULTS: Both patients had novel mutations in the PHEX gene; one patient had a frameshift mutation, c.931dupC, which caused early termination of translation and produced the truncated protein p.Gln311Profs*13; the other patient had a splice site mutation, IVS14+1G>A, which caused the skipping of exon 15 and produced an incomplete amino acid chain. Their parents had normal gene phenotypes. CONCLUSIONS: c.931dupC and IVS14+1G>A are two novel mutations of the PHEX gene and might be the new pathogenic mutations of XLH.
[Mh] Termos MeSH primário: Raquitismo Hipofosfatêmico Familiar/genética
Mutação
Endopeptidase Neutra Reguladora de Fosfato PHEX/genética
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Feminino
Sequenciamento de Nucleotídeos em Larga Escala
Humanos
Masculino
Estudos Retrospectivos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.24.- (PHEX Phosphate Regulating Neutral Endopeptidase); EC 3.4.24.- (PHEX protein, human)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE


  2 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28045985
[Au] Autor:Li D; Zhang L; Zuo L; Jin CG; Li WG; Chen JB
[Ad] Endereço:Department of Nephrology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
[Ti] Título:Association of CKD-MBD Markers with All-Cause Mortality in Prevalent Hemodialysis Patients: A Cohort Study in Beijing.
[So] Source:PLoS One;12(1):e0168537, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The relationships between all-cause mortality and serum intact parathyroid hormone (iPTH), calcium, and phosphate are fairly diverse in patients on maintenance hemodialysis according to prior studies. This study evaluated the association of chronic kidney disease-mineral and bone disorder (CKD-MBD) markers with all-cause mortality in prevalent hemodialysis patients from 2007 to 2012 in Beijing, China. A cohort, involving 8530 prevalent hemodialysis patients who had undergone a 6-70 months follow-up program (with median as 40 months) was formed. Related data was recorded from the database in 120 hemodialysis centers of Beijing Health Bureau (2007 to 2012). Information regarding baseline demographics, blood CKD-MBD markers and all-cause mortality was retrospectively reviewed. By using multivariate Cox regression model analysis, patients with a low iPTH level at baseline were found to have greater risk of mortality (<75pg/ml, HR = 1.36, 95% confidence interval (CI) 1.16-1.60) than those with a baseline iPTH level within 150-300 pg/ml. Similarly, death risk showed an increase when the baseline serum calcium presented a low level (<2.1mmol/L, HR = 1.54; 95% CI 1.37-1.74). Levels of baseline serum phosphorus were not associated with the risk of death. Similar results appeared through the baseline competing risks regression analysis. Patients with a lower level of serum iPTH or calcium are at a higher risk of all-cause mortality compared with those within the range recommended by Kidney Disease Outcome Quality Initiative (KDOQI) guidelines.
[Mh] Termos MeSH primário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/diagnóstico
Mortalidade
Diálise Renal
[Mh] Termos MeSH secundário: Adulto
Idoso
Pequim/epidemiologia
Biomarcadores/sangue
Cálcio/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Feminino
Humanos
Masculino
Meia-Idade
Hormônio Paratireóideo/sangue
Fósforo/sangue
Modelos de Riscos Proporcionais
Qualidade da Assistência à Saúde
Análise de Regressão
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Parathyroid Hormone); 27YLU75U4W (Phosphorus); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170103
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0168537


  3 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28083765
[Au] Autor:Fukagawa M; Inaba M; Yokoyama K; Shigematsu T; Ando R; Miyamoto KI; For Japan CKD-MBD Forum
[Ad] Endereço:Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan. fukagawa@tokai-u.jp.
[Ti] Título:An introduction to CKD-MBD research: restart for the future.
[So] Source:Clin Exp Nephrol;21(Suppl 1):1-3, 2017 Mar.
[Is] ISSN:1437-7799
[Cp] País de publicação:Japan
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Ósseas Metabólicas/etiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia
Minerais/metabolismo
Insuficiência Renal Crônica/complicações
Pesquisa
[Mh] Termos MeSH secundário: Doenças Ósseas Metabólicas/quimioterapia
Doenças Ósseas Metabólicas/metabolismo
Distúrbio Mineral e Ósseo na Doença Renal Crônica/quimioterapia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo
Previsões
Humanos
Insuficiência Renal Crônica/quimioterapia
Insuficiência Renal Crônica/metabolismo
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Minerals)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170113
[St] Status:MEDLINE
[do] DOI:10.1007/s10157-016-1372-7


  4 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28062938
[Au] Autor:Fujii H; Joki N
[Ad] Endereço:Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan.
[Ti] Título:Mineral metabolism and cardiovascular disease in CKD.
[So] Source:Clin Exp Nephrol;21(Suppl 1):53-63, 2017 Mar.
[Is] ISSN:1437-7799
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The mineral bone disorder of CKD, called Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), has a major role in the etiology and progression of cardiovascular disease in CKD patients. Since the main emphasis in CKD-MBD is on three categories (bone abnormalities, laboratory abnormalities, and vascular calcifications), we have routinely accepted ectopic cardiovascular calcifications as a central risk factor in the pathophysiology of CKD-MBD for cardiac events. However, recent compelling evidence suggests that some CKD-MBD-specific factors other than vascular calcification might contribute to the onset of cardiovascular disease. Most notable is fibroblast growth factor-23 (FGF23), which is thought to be independently associated with cardiac remodeling. Slow progression of cardiac disorders, such as vascular calcification and cardiac remodeling, characterizes cardiac disease due to CKD-MBD. In contrast, fatal arrhythmia may be induced when QT prolongation occurs with CKD-MBD treatment, such as with lower Ca dialysate or the use of calcimimetics. Sudden onset of fatal cardiac events, such as heart failure and sudden cardiac death, due to fatal arrhythmia would be another distinctive phenomenon of CKD-MBD. This may be defined as CKD-MBD-specific cardiac complex syndrome.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/etiologia
Doenças Cardiovasculares/metabolismo
Minerais/metabolismo
Insuficiência Renal Crônica/complicações
Insuficiência Renal Crônica/metabolismo
[Mh] Termos MeSH secundário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo
Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Minerals)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1007/s10157-016-1363-8


  5 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28005175
[Au] Autor:Mizobuchi M; Ogata H; Koiwa F; Kinugasa E; Akizawa T
[Ad] Endereço:Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
[Ti] Título:Research on kidney and mineral metabolism in Japan: past, present, and future.
[So] Source:Clin Exp Nephrol;21(Suppl 1):4-8, 2017 Mar.
[Is] ISSN:1437-7799
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Since the identification of the kidney was the main site for the synthesis of calcitriol (1α, 25-dihydroxycholecalciferol), research on chronic kidney disease (CKD)-associated mineral metabolism disorders and their management has made rapid progress. Various active analogues of calcitriol have clinically become available for treating secondary hyperparathyroidism (SHPT), which is a representative mineral metabolism abnormality in CKD patients. A calcimimetic compound cinacalcet hydrochloride has also been developed for the medical management of SHPT through a different mechanism involving the calcium-sensing receptor. The concept of CKD-mineral and bone disorder (CKD-MBD) was proposed in 2006 to provide a comprehensive understanding of a disorder related to mineral metabolism abnormalities of CKD, based on the fact that these abnormalities are closely associated with cardiovascular disease as well as bone disorders (renal osteodystrophy). There has been a recent surge in the development of phosphate binders for CKD-MBD, focused on an effort to improve mortality. In Japan, high-quality basic and clinical research on CKD-MBD has led to the development of novel therapeutic drugs, such as maxacalcitol, falecalcitriol, and bixalomer. New practice guidelines have been published and are widely adapted in clinical practice.
[Mh] Termos MeSH primário: Distúrbio Mineral e Ósseo na Doença Renal Crônica/história
Rim/metabolismo
Minerais/metabolismo
Insuficiência Renal Crônica/história
[Mh] Termos MeSH secundário: Animais
Distúrbio Mineral e Ósseo na Doença Renal Crônica/quimioterapia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia
História do Século XX
História do Século XXI
Humanos
Hiperparatireoidismo Secundário
Japão
Hormônio Paratireóideo/metabolismo
Insuficiência Renal Crônica/complicações
Insuficiência Renal Crônica/quimioterapia
Pesquisa
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Minerals); 0 (Parathyroid Hormone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1007/s10157-016-1366-5


  6 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28248961
[Au] Autor:Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
[Ad] Endereço:Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
[Ti] Título:Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
[So] Source:PLoS One;12(3):e0171028, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic kidney disease-mineral and bone disorder (CKD-MBD), a complication of chronic kidney disease, has been linked to reduced quality and length of life. High serum phosphate levels that result from CKD-MBD require phosphate-lowering agents, also known as phosphate binders. The objective of this systematic review is to compare the effects of available phosphate binders on laboratory outcomes in patients with CKD-MBD. METHODS: Data sources included MEDLINE and EMBASE from January 1996 to April 2016, and the Cochrane Register of Controlled Trials up to April 2016. Teams of two reviewers, independently and in duplicate, screened titles and abstracts and potentially eligible full text reports to determine eligibility, and subsequently abstracted data and assessed risk of bias in eligible randomized controlled trials (RCTs). Eligible trials enrolled patients with CKD-MBD and randomized them to receive calcium-based phosphate binders (delivered as calcium acetate, calcium citrate or calcium carbonate), non-calcium-based phosphate binders (NCBPB) (sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate, sucroferric oxyhydroxide and ferric citrate), phosphorus restricted diet (diet), placebo or no treatment and reported effects on serum levels of phosphate, calcium and parathyroid hormone. We performed Bayesian network meta-analyses (NMA) to calculate the effect estimates (mean differences) and 95% credible intervals for serum levels of phosphate, calcium and parathyroid hormone. We calculated direct, indirect and network meta-analysis estimates using random-effects models. We applied the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to rate the quality of evidence for each pairwise comparison. RESULTS: Our search yielded 1108 citations; 71 RCTs were retrieved for full review and 16 proved eligible. Including an additional 13 studies from a previous review, 29 studies that enrolled 8335 participants proved eligible; 26 trials provided data for quantitative synthesis. Sevelamer, lanthanum, calcium, iron, diet and combinations of active treatments (calcium or sevelamer or lanthanum and combination of calcium and sevelamer) resulted in significantly lower serum phosphate as compared to placebo (moderate to very low quality of evidence). We found no statistically significant differences between active treatment categories in lowering serum phosphate. Sevelamer, lanthanum and diet resulted in lower serum calcium compared to calcium (moderate quality evidence for lanthanum and diet; low quality evidence for Sevelamer). Iron, sevelamer and calcium yielded lower parathyroid hormone levels as compared to lanthanum. Meta-regression analyses did not yield a statistically significant association between treatment effect and trial duration. DISCUSSION/CONCLUSIONS: We found few differences between treatments in impact on phosphate and differences in parathyroid hormone. Relative to calcium, sevelamer, lanthanum and diet showed significant reduction in serum calcium from baseline. Treatment recommendations should be based on impact on patient-important outcomes rather than on surrogate outcomes. Systematic review registration: PROSPERO CRD-42016032945.
[Mh] Termos MeSH primário: Cálcio/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia
Hormônio Paratireóideo/sangue
Fosfatos/sangue
[Mh] Termos MeSH secundário: Feminino
Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Parathyroid Hormone); 0 (Phosphates); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170301
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171028


  7 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28120569
[Au] Autor:Kwon YE; Lee MJ; Park KS; Han SH; Yoo TH; Oh KH; Lee J; Lee KB; Chung W; Kim YH; Ahn C; Choi KH
[Ad] Endereço:Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients.
[So] Source:Yonsei Med J;58(2):380-387, 2017 Mar.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Recent studies have reported that loss of bone mass is associated with renal function decline and increased fracture risks in chronic kidney disease (CKD) patients. The aim of this study was to investigate the best estimated glomerular filtration rate (eGFR) equation to detect osteopenia in CKD patients. MATERIALS AND METHODS: This was a cross-sectional study, and 780 patients aged 50 years or above were classified into normal bone mass or osteopenia groups according to the -1.0 of T-scores at total hip and femur neck. Comparisons of area under the receiver operating characteristic (ROC) curves (AUC) were performed to investigate significant differences among three eGFR formulas: Modification of Diet in Renal Disease, CKD-Epidemiology Collaboration (EPI) creatinine, and CKD-EPI cystatin C (CKD-EPI-Cys). RESULTS: The mean age was 61 years old and the proportion of females was 37.3%. The total hip osteopenia group showed lower CKD-EPI-Cys eGFR levels (osteopenia group, 33.3±19.0 mL/min/1.73 m²; normal group, 48.1±26.2 mL/min/1.73 m², p<0.001). In multiple logistic regression analysis, CKD-EPI-Cys eGFR was independently associated with osteopenia at the total hip (per 1 mL/min/1.73 m² increase, odds ratio 0.98, 95% confidence interval 0.97-0.99, p=0.004) after adjusting for confounding variables. ROC curve analyses indicated that CKD-EPI-Cys shows the largest AUC for osteopenia at the total hip (AUC=0.678, all p<0.01) and the femur neck (AUC=0.665, all p<0.05). CONCLUSION: Decreased renal function assessed by CKD-EPI-Cys equation correlates with osteopenia better than creatinine-based methods in CKD patients, and the CKD-EPI-Cys formula might be a useful tool to assess skeletal-related event risks.
[Mh] Termos MeSH primário: Doenças Ósseas Metabólicas/diagnóstico
Distúrbio Mineral e Ósseo na Doença Renal Crônica/diagnóstico
Creatinina/sangue
Cistatina C/sangue
Taxa de Filtração Glomerular
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores/sangue
Doenças Ósseas Metabólicas/sangue
Doenças Ósseas Metabólicas/fisiopatologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue
Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia
Estudos Transversais
Feminino
Humanos
Masculino
Meia-Idade
Curva ROC
Insuficiência Renal Crônica/sangue
Insuficiência Renal Crônica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cystatin C); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170125
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2017.58.2.380


  8 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27966253
[Au] Autor:Lindhard K; Broberg B; Groenberg H; Post Hansen H
[Ad] Endereço:Nephrology, Herlev Hospital, Herlev, Denmark.
[Ti] Título:Treatment of a soft tissue calcification in a patient receiving peritoneal dialysis.
[So] Source:Hemodial Int;21(2):E34-E39, 2017 Apr.
[Is] ISSN:1542-4758
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:Chronic Kidney Disease patients suffer from Mineral and Bone Disorder (CKD-MBD) leading to increased vascular and soft-tissue calcification. The prevalence of soft tissue calcification in dialysis patients is not well described, and most cases describe such calcifications in hemodialysis patients. We describe a case of a massive soft tissue calcification in the right gluteal region in a peritoneal dialysis patient. The patient had severe pain and were disabled. The treatment was converted to an intensive hemodialysis regimen with a minimal calcium load and high dose of cinacalcet. During the treatment, the calcification diminished rapidly from a diameter of 26.6 to 2.9 cm, and the patient symptoms were relieved, leaving the patient with no pain or restriction in mobilization.
[Mh] Termos MeSH primário: Cálcio/metabolismo
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia
Diálise Peritoneal/efeitos adversos
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Idoso
Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia
Feminino
Humanos
Insuficiência Renal Crônica/terapia
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
SY7Q814VUP (Calcium)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161214
[St] Status:MEDLINE
[do] DOI:10.1111/hdi.12519


  9 / 7464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28452729
[Au] Autor:Dunamalyan R; Mardiyan M; Danielyan L; Mkrtchyan S; Chopikyan A
[Ad] Endereço:Yerevan State Medical University after M. Heratsi, Department of Health Governance and Economics; Department of ENT, Armenia.
[Ti] Título:QUALITY OF LIFE OF CHILDREN WITH RICKETS IN YOUNG AGE IN ARMENIA.
[So] Source:Georgian Med News;(263):60-64, 2017 Feb.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:eng
[Ab] Resumo:Quality of Life (QL) currently is one of the most important criteria for evaluating a child's function. The main characteristics of QL in pediatrics are the psychological, physical and social functioning of the body. Integral characteristics of QOL based on the subjective perception of the components of the child and his parents. As a result of the official statistics and our research it turned out that children in this age-group more often suffer from intestinal infections, anemia, hypertrophy, rickets, skin and subcutaneous fiber disease, deficiencies occurring in prenatal period. The aim of the research is to evaluate the peculiarities of QL criteria change in case of rickets. So far in Armenia there were no tools of QL assessment of children of an early age, thereby the most acceptable questionnaire of QUALIN was used to create Armenian version on its basis. We cooperated with MAPI institute and the authors of QUALIN(Qualite de vie du Nourisson) questionnaire (Manificat S., Dazord A,) and got MAPI's permission to apply the questionnaire in the Republic of Armenia. The questionnaire QUALIN was selected for studying children's QL. The results show that the QL of children with rickets is lower than the QL of the ones who are healthy. The difference is more vividly expressed in the following parameters of QL: neuropsychological development and physical health, the ability to stay alone. In this case the pediatricians have given lower mark of QL than parents. We think that one of the possible motives of such diversity is the professional approach of doctors who estimated the QL more strictly than parents did. So QUALIN international questionnaire can be applied to estimate the peculiarities of QL criteria change of children with rickets at an early age.
[Mh] Termos MeSH primário: Qualidade de Vida
Raquitismo/psicologia
[Mh] Termos MeSH secundário: Armênia
Pré-Escolar
Feminino
Humanos
Lactente
Recém-Nascido
Masculino
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE


  10 / 7464 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28298956
[Au] Autor:Suki WN; Moore LW
[Ad] Endereço:Houston Methodist Hospital, Houston, Texas.
[Ti] Título:Phosphorus Regulation in Chronic Kidney Disease.
[So] Source:Methodist Debakey Cardiovasc J;12(4 Suppl):6-9, 2016 Oct-Dec.
[Is] ISSN:1947-6108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Serum phosphorus levels stay relatively constant through the influence of multiple factors-such as parathyroid hormone, fibroblast growth factor 23, and vitamin D-on the kidney, bone, and digestive system. Whereas normal serum phosphorus ranges between 3 mg/dL to 4.5 mg/dL, large cross-sectional studies have shown that even people with normal kidney function are sometimes found to have levels ranging between 1.6 mg/dL and 6.2 mg/dL. While this may partially be due to diet and the factors mentioned above, total understanding of these atypical ranges of serum phosphorus remains uncertain. Risks for bone disease are high in people aged 50 and older, and this group comprises a large proportion of people who also have chronic kidney disease. Consuming diets low in calcium and high in phosphorus, especially foods with phosphate additives, further exacerbates bone turnover. Existing bone disease increases the risk for high serum phosphorus, and higher serum phosphorus has been associated with increased adverse events and cardiovascular-related mortality both in people with chronic kidney disease and in those with no evidence of disease. Once kidney function has deteriorated to end-stage disease (Stage 5), maintaining normal serum phosphorus requires dietary restrictions, phosphate-binding medications, and dialysis. Even so, normal serum phosphorus remains elusive in many patients with Stage 5 kidney disease, and researchers are testing novel targets that may inhibit intestinal transport of phosphorus to achieve better phosphate control. Protecting and monitoring bone health should also aid in controlling serum phosphorus as kidney disease advances.
[Mh] Termos MeSH primário: Osso e Ossos/metabolismo
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo
Falência Renal Crônica/metabolismo
Rim/metabolismo
Fósforo na Dieta/metabolismo
Insuficiência Renal Crônica/metabolismo
[Mh] Termos MeSH secundário: Idoso
Remodelação Óssea
Osso e Ossos/fisiopatologia
Quelantes/uso terapêutico
Distúrbio Mineral e Ósseo na Doença Renal Crônica/epidemiologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia
Progressão da Doença
Feminino
Humanos
Absorção Intestinal
Rim/fisiopatologia
Falência Renal Crônica/epidemiologia
Falência Renal Crônica/fisiopatologia
Falência Renal Crônica/terapia
Masculino
Fósforo na Dieta/administração & dosagem
Fósforo na Dieta/sangue
Prevalência
Recomendações Nutricionais
Diálise Renal
Insuficiência Renal Crônica/epidemiologia
Insuficiência Renal Crônica/fisiopatologia
Insuficiência Renal Crônica/terapia
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chelating Agents); 0 (Phosphorus, Dietary)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.14797/mdcj-12-4s1-6



página 1 de 747 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde